Seer signs agreement with Sciex: Seer and SCIEX have signed a commercial agreement to provide end to end unbiased proteomics solutions.
Seer adds board members: Seer appoints Deep Nishar and Mostafa Ronaghi, Ph.D. to its Board of Directors
Seer and Bruker Sign Commercial Agreement to Expand Market for Unbiased, Deep Proteomics
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Proteomics
Seer announced the pricing of its initial public offering of 9,210,527 shares of Class A common stock.
Seer Appoints Catherine Friedman to its Board of Directors
Seer Announces Spin Out of PrognomIQ with $55 Million Initial Financing
Seers Announces Publication in Nature Communications Demonstrating Performance, Scalability and Utility of its Platform Technology for Deep, Unbiased Proteomics.